Literature DB >> 7686030

Circulating megakaryocyte progenitors in myeloproliferative disorders are hypersensitive to interleukin-3.

S Kobayashi1, M Teramura, S Hoshino, T Motoji, K Oshimi, H Mizoguchi.   

Abstract

Previous studies have reported that megakaryocyte progenitors in myeloproliferative disorders (MPD) formed spontaneous megakaryocyte colonies without the addition of megakaryocyte colony-stimulating factor (Meg-CSF). To determine whether this spontaneous colony formation is due to autocrine proliferation of MPD megakaryocyte progenitors or to hypersensitivity to Meg-CSF that might exist in the culture system, we investigated colony-forming unit-megakaryocytes (CFU-Meg) in the peripheral blood of 11 MPD patients, using serum-free cultures. Spontaneous megakaryocyte colonies were observed in serum-free cultures of nonadherent mononuclear cells (NAdMNC) obtained from MPD patients with thrombocytosis, whereas the NAdMNC of MPD patients without thrombocytosis, that of patients with reactive thrombocytosis and normal subjects never formed spontaneous colonies. However, the spontaneous colonies from MPD patients with thrombocytosis disappeared in cultures using highly purified CD34-positive cells as target cells. To study the hypersensitivity of megakaryocyte progenitors to Meg-CSF, dose-response experiments were performed with interleukin-3 (IL-3). CFU-Meg from MPD patients with thrombocytosis showed maximal growth at the concentrations of IL-3 lower than those for normal subjects. CFU-Meg of MPD patients without thrombocytosis and that of patients with reactive thrombocytosis showed the same colony growth response to IL-3 as that of normal subjects. This result indicates that the CFU-Meg of MPD patients with thrombocytosis are hypersensitive to IL-3. It also suggests that spontaneous colony formation by NAdMNC is not due to the autocrine growth of megakaryocyte progenitors but is due to the hypersensitivity of megakaryocyte progenitors to Meg-CSF, such as IL-3, released by accessory cells. Furthermore, it is possible that such hypersensitivity of CFU-Meg to IL-3 might be a pathogenic factor in MPD with accompanying thrombocytosis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7686030     DOI: 10.1111/j.1365-2141.1993.tb04688.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  6 in total

Review 1.  Basic sciences of the myeloproliferative diseases: pathogenic mechanisms of ET and PV.

Authors:  Rosemary E Gale
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

2.  Molecular detection of c-mpl thrombopoietin receptor gene expression in chronic myeloproliferative disorders.

Authors:  S Duensing; A Duensing; J G Meran; A Kreft; G Büsche; A Ganser; A Georgii
Journal:  Mol Pathol       Date:  1999-06

Review 3.  The pathogenesis of chronic myeloproliferative diseases.

Authors:  A Tefferi
Journal:  Int J Hematol       Date:  2001-02       Impact factor: 2.490

4.  Complex oncogene dependence in microRNA-125a-induced myeloproliferative neoplasms.

Authors:  Shangqin Guo; Haitao Bai; Cynthia M Megyola; Stephanie Halene; Diane S Krause; David T Scadden; Jun Lu
Journal:  Proc Natl Acad Sci U S A       Date:  2012-09-24       Impact factor: 11.205

5.  The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation.

Authors:  Catriona H M Jamieson; Jason Gotlib; Jeffrey A Durocher; Mark P Chao; M Rajan Mariappan; Marla Lay; Carol Jones; James L Zehnder; Stan L Lilleberg; Irving L Weissman
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-07       Impact factor: 11.205

Review 6.  Myelofibrosis: pathogenesis of myelofibrosis with myeloid metaplasia. French INSERM Research Network on Myelofibrosis with Myeloid Metaplasia.

Authors:  M C Le Bousse-Kerdilès; M C Martyré
Journal:  Springer Semin Immunopathol       Date:  1999
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.